A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Moderate to Severe Plaque Psoriasis
Sponsor: Celltrion
Listed as NCT04673786, this PHASE3 trial focuses on Psoriasis and remains completed. Sponsored by Celltrion, it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2022 — Jul 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE3
▶ Show 3 earlier versions
-
Sep 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Celltrion
For direct contact, visit the study record on ClinicalTrials.gov .